Biotechnology
Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs
Creative Biolabs has introduced specialized neuroscience research platforms targeting Alzheimer's and other neurodegenerative diseases, providing critical tools for studying cellular mechanisms in both peripheral and central nervous systems to accelerate drug development and mechanistic studies.
Ocumetics Completes One-Month Postoperative Examinations for Revolutionary Intraocular Lens
Ocumetics Technology Corp. has completed critical one-month postoperative examinations for its innovative accommodating intraocular lens, marking a significant milestone in developing a potential vision correction solution that could eliminate the need for glasses or contact lenses.
Oncotelic Therapeutics Featured in Editorial Highlighting Innovative Cancer and Rare Disease Pipeline
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial underscores the company's growing prominence in developing RNA-based and immunotherapy treatments for aggressive cancers and pediatric rare diseases, positioning it for significant market growth.
Hong Kong and GBA Cities Forge Biomedical Partnership Driving Global Innovation Leadership
Hong Kong's biomedical sector has grown nearly 30% in the past decade, with collaborative efforts across the Greater Bay Area positioning the region as a global biotech innovation hub through financial resources, clinical trial capabilities, and cross-border partnerships.
Onassis Holdings Launches $75 Million Regulation A+ Financing Round with Dalmore Group
Biotech company Onassis Holdings has initiated a Regulation A+ financing round through Dalmore Group, enabling public investment of up to $75 million annually to advance its epigenetic rejuvenation technologies.
Oncotelic Therapeutics Advances RNA-Based and Immunotherapy Pipeline to Address Unmet Medical Needs in Cancer and Rare Diseases
Oncotelic Therapeutics is leveraging AI and nanomedicine to develop breakthrough treatments for aggressive cancers and pediatric rare diseases, positioning the company alongside industry leaders in transforming biotech innovation.
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar Showcasing Alcohol Metabolism Beverage Opportunity
Unbuzzd Wellness, licensee of Quantum BioPharma, will host an investor webinar on September 16, 2025, to present clinical data and sales strategies for its scientifically proven alcohol metabolism beverage, highlighting a significant investment opportunity in the growing wellness market.
NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025
NanoViricides will showcase its clinical-stage nanoviricide technology targeting multiple viral diseases at the LSX World Congress, highlighting its potential to address unmet medical needs through a novel antiviral approach.
Oncotelic Therapeutics Engages IBN to Lead Corporate Communications Strategy
Oncotelic Therapeutics has selected IBN to manage its corporate communications as the company advances its RNA-based immunotherapy pipeline, including a Phase 3 pancreatic cancer treatment, highlighting strategic positioning for future clinical and regulatory milestones.
Soligenix Expands Rare Disease and Public Health Pipeline in Latest Corporate Strategy Update
Soligenix Inc. showcases its dual-focused strategy addressing both rare diseases with unmet medical needs and critical public health threats through its latest corporate presentation, positioning the company as a significant player in specialized therapeutics and biodefense solutions.
VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome
VolitionRx has signed an agreement with Werfen to evaluate its Nu.Q NETs assay for improved detection and monitoring of antiphospholipid syndrome, potentially transforming diagnosis and management for millions of patients worldwide.
Gyre Therapeutics Advances Hydronidone Toward China Approval and Expands Clinical Pipeline
Gyre Therapeutics has submitted Hydronidone for approval in China and initiated a U.S. Phase 2 trial, positioning the company for significant growth in liver fibrosis treatment markets.
OS Therapies Advances Toward 2026 Osteosarcoma Drug Launch with FDA RMAT Designation
OS Therapies Inc. achieves critical regulatory milestones for its OST-HER2 immunotherapy, positioning for potential accelerated approval and U.S. commercial launch in 2026 to address a 40-year treatment gap in osteosarcoma.
Helix BioPharma Abandons GEM Financing Deal After Strategic Review
Helix BioPharma has decided against proceeding with a previously announced equity financing facility with GEM, citing misalignment with its capital strategy and commitment to shareholder value, while continuing to explore alternative funding options for its oncology pipeline.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Renaissance BioScience Secures Australian Patent for Revolutionary RNA Production Technology
Renaissance BioScience has obtained an Australian patent for its yeast-based RNA production platform, enabling cost-effective RNA applications in agriculture, animal health, and human medicine with significant market potential.
BRAIN Biotech AG Appoints New Executive Vice President to Lead Enzyme Products Division
BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of its enzyme products business, signaling a strategic move to strengthen its position in the growing biocatalysts market and enhance integration between research and production capabilities.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
Kairos Pharma to Present at H.C. Wainwright Global Investment Conference
Kairos Pharma's participation in the prestigious H.C. Wainwright conference provides crucial visibility for its innovative cancer therapeutic ENV105, which addresses significant unmet medical needs in drug-resistant cancers.
GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
Sigyn Therapeutics Expands Cardiovascular Disease Study to Target Lipoprotein Reduction
Sigyn Therapeutics plans a clinical feasibility study of its blood purification technology that could address cardiovascular disease in high-risk patients while potentially extending lives of end-stage renal disease patients and generating significant economic impact.
Soligenix CEO to Present at H.C. Wainwright Global Investment Conference
Soligenix Inc.'s CEO presentation at the upcoming investment conference highlights the company's progress in developing treatments for rare diseases and vaccines for public health threats, signaling important advancements for investors and patients.
Clene Inc. to Present at H.C. Wainwright Global Investment Conference
Clene Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage clinical developments in neurodegenerative disease treatments.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Cybin Appoints Co-Founder Eric So as Interim CEO Following Drysdale's Departure
Cybin Inc. has appointed co-founder Eric So as interim CEO following Doug Drysdale's resignation, a leadership transition that comes as the company advances its late-stage psychedelic-based treatments for mental health disorders.
Scinai Immunotherapeutics Reports Strong First-Half 2025 Results with Revenue Growth and Improved Cash Position
Scinai Immunotherapeutics demonstrated significant financial improvement in the first half of 2025, with revenue growth, reduced losses, and strengthened liquidity, positioning the company for continued advancement of its anti-IL-17 NanoAb program and CDMO business expansion.
Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
Calidi Biotherapeutics will showcase its innovative RedTail platform at the H.C. Wainwright conference, highlighting its potential to revolutionize cancer treatment through systemic delivery of genetic medicines to metastatic sites.
IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering Research
IntegrateRNA's new Aminoacyl-tRNA In Vitro Synthesis Service enables researchers to create custom proteins with non-canonical amino acids, potentially accelerating drug discovery and biotechnology development.
CD BioGlyco Expands Glycobiology Research Capabilities with Custom Glycoconjugate Synthesis Service
CD BioGlyco's new custom glycoconjugate synthesis service enables researchers to study glycan functions in cell recognition and immune responses, advancing biomedical research capabilities.
Creative Biolabs Advances Biopharmaceutical Innovation Through Glycobiology Expertise
Creative Biolabs is enhancing biopharmaceutical development through advanced glycoprotein engineering and polysaccharide analysis technologies that improve drug efficacy, safety, and stability.